Abstract
Ticarcillin was administered as initial therapy during 73 episodes of infections occurring in 69 adults with neoplastic diseases. During the first six infections, doses of 5 gm were dissolved in 200 ml of solvent and administered intravenously over a 2-h period every 6 h. Four of six infections responded to therapy. However, two of the five Pseudomonas infections failed to respond, whereas the organisms causing the infection were sensitive to ticarcillin in vitro. During the remaining 67 infections, doses of 3.5 g were similarly dissolved and administered intravenously over a 2-h period every 4 h. The overall response to ticarcillin in these 67 infections was 43%. However, 18 of 20 Pseudomonas infections, three Proteus spp. infections, and one infection caused by H. influenzae responded. Only 1 of 7 infections caused by mixed organisms and 5 of 13 infections in which the etiologic agent could not be identified responded. Ticarcillin was ineffective against the majority of Escherichia coli and Klebsiella spp. infections, organisms which were resistant to ticarcillin in vitro. The majority of patients were neutropenic, but the response rate was not dependent on the number of circulating polymorphonuclear neutrophilic leukocytes. Superinfection occurred in seven patients. Erythematous skin rash occurred in two patients, which subsided after discontinuation of the drug. No liver or renal toxicity occurred that could be attributed to ticarcillin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Altemeier W. A., Todd J. C., Inge W. W. Gram-negative septicemia: a growing threat. Ann Surg. 1967 Oct;166(4):530–542. doi: 10.1097/00000658-196710000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P., Deerhake B. In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol. 1971 Jan;21(1):61–65. doi: 10.1128/am.21.1.61-65.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P., Middleman E., Umsawadi T., Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer. 1972 Jun;29(6):1697–1701. doi: 10.1002/1097-0142(197206)29:6<1697::aid-cncr2820290638>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Rodriguez V., Luce J. K. Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci. 1969 Jun;257(6):408–414. doi: 10.1097/00000441-196906000-00007. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Whitecar J. P., Jr, Middleman E., Rodriguez V. Carbenicillin therapy for pseudomonas infections. JAMA. 1971 Oct 4;218(1):62–66. [PubMed] [Google Scholar]
- HERSH E. M., BODEY G. P., NIES B. A., FREIREICH E. J. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA. 1965 Jul 12;193:105–109. doi: 10.1001/jama.1965.03090020019005. [DOI] [PubMed] [Google Scholar]
- Middleman E. L., Watanabe A., Kaizer H., Bodey G. P. Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972 Aug;30(2):573–579. doi: 10.1002/1097-0142(197208)30:2<573::aid-cncr2820300238>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Swarz H. Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med. 1969 Nov;71(5):903–911. doi: 10.7326/0003-4819-71-5-903. [DOI] [PubMed] [Google Scholar]
- Rodriguez V., Inagaki J., Bodey G. P. Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother. 1973 Jul;4(1):31–36. doi: 10.1128/aac.4.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sutherland R., Burnett J., Rolinson G. N. -carboxy-3-thienylmethylpenicillin (BRL 2288), a new semisynthetic penicillin: in vitro evaluation. Antimicrob Agents Chemother (Bethesda) 1970;10:390–395. [PubMed] [Google Scholar]